BBM mitigates liver lipid metabolism disorders by modulating the SIRT1/LKB1/AMPK pathway, regulating the expression of autophagy markers LC3a/b, Beclin 1, and p62, and inducing autophagy to decelerate the progression of NAFLD. Here, MAP1LC3A is linked to digestive system neoplasm.